Sign Out
Administration of Favipiravir should be careful for patients, such as: Woman of childbearing potential should have negative result test of pregnancy before the treatment started. If pregnancy occur during the treatment, the treatment should be stopped.
When Favipiravir is going to be used in breastfeeding women, breast-feeding must be stopped due to active metabolite of Favipiravir distributed in human milk.
Favipiravir is distributed in sperm. When the drug is going to be used in man, give thorough explanation about the risk and instructs: to use most effective contraception method in sexual intercourse during the treatment and for 7 days after treatment (men must wear a condom), not to have sexual intercourse with pregnant woman.
Although causal effect correlation have not known, psychoneurotic symptoms, such as abnormal behaviors, were reported after administering Favipiravir. Their families must be made aware of the following precautionary points to avoid rare accidents such as falls due to abnormal behaviour. Patients or their families should be informed to take preventive measures after Favipiravir administration such as to look after for at least 2 days after patients if they are treated at home.
Favipiravir should be given with caution in gout patients or patients who has a history of gout hyperuricemia patients since uric acid can be increased and worsening the symptoms.
Favipiravir should be given with caution to elderly patients and monitored regularly.
The administration Favipiravir in children have not been established.
In in-vitro study, Favipiravir inhibited the current hERG at the Cmax which 3 times higher than Cmax in human dose, so that the risk of QT interval prolongation of Favipiravir at therapeutic dose considered to be low.
